Publications

Authors:

Merli, Michele; Ferrarini, Isacco; Merli, Francesco; Busca, Alessandro; Mina, Roberto; Falini, Brunangelo; Bruna, Riccardo; Cairoli, Roberto; Marchetti, Monia; Romano, Alessandra; Cavo, Michele; Arcaini, Luca; Trentin, Livio; Cattaneo, Chiara; Derenzini, Enrico; Fracchiolla, Nicola Stefano; Marchesi, Francesco; Scattolin, Annamaria; Billio, Atto; Bocchia, Monica; Massaia, Massimo; Gambacorti-Passerini, Carlo; Mauro, Francesca Romana; Gentile, Massimo; Mohamed, Sara; Della Porta, Matteo Giovanni; Coviello, Elisa; Cilloni, Daniela; Visani, Giuseppe; Federici, Augusto Bramante; Tisi, Maria Chiara; Cudillo, Laura; Galimberti, Sara; Gherlinzoni, Filippo; Pagano, Livio; Guidetti, Anna; Bertù, Lorenza; Corradini, Paolo; Passamonti, Francesco; Visco, Carlo

Title:

SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort

Year:

2022

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Format:

A Stampa

Referee:

Sì

Name of journal:

Hematological Oncology

ISSN of journal:

0278-0232

Page numbers:

1-11

Keyword:

BTK inhibitors; COVID-19; SARS-CoV-2; chronic lymphocytic leukemia; outcome

Short description of contents:

COVID-19, the disease caused by SARS-CoV-2, is still afflicting thousands of people across the globe. Few studies on COVID-19 in chronic lymphocytic leukemia (CLL) are available. Here, we analyzed data from the CLL cohort of the Italian Hematology Alliance on COVID-19 (NCT04352556), which included 256 CLL patients enrolled between 25 February 2020 and 1 February 2021. Median age was 70 years (range 38-94) with male preponderance (60.1%). Approximately half of patients (n = 127) had received at least one line of therapy for CLL, including 108 (83.7%) who were on active treatment at the time of COVID-19 or received their last therapy within 12 months. Most patients (230/256, 89.9%) were symptomatic at COVID-19 diagnosis and the majority required hospitalization (n = 176). Overall, after a median follow-up of 42 days (IQR 24-96), case fatality rate was 30.1%, and it was 37.5% and 24.4% in the first (25 February 2020-22 June 2020) and second wave (23 June 2020-1 February 2021), respectively (p = 0.03). At multivariate analysis, male sex (HR 1.82, 95% CI 1.03-3.24, p = 0.04), age over than 70 years (HR 2.23, 95% CI 1.23-4.05, p = 0.01), any treatment for CLL given in the last 12 months (HR 1.72, 95% CI 1.04-2.84, p = 0.04) and COVID-19 severity (severe: HR 5.66, 95% CI 2.62-12.33, p < 0.0001; critical: HR 15.99, 95% CI 6.93-36.90, p < 0.0001) were independently associated with poor survival. In summary, we report a dismal COVID-related outcome in a significant fraction of CLL patients, that can be nicely predicted by clinical parameters.

Product ID:

130954

Handle IRIS:

11562/1081766

Last Modified:

May 31, 2023

Bibliographic citation:

Merli, Michele; Ferrarini, Isacco; Merli, Francesco; Busca, Alessandro; Mina, Roberto; Falini, Brunangelo; Bruna, Riccardo; Cairoli, Roberto; Marchetti, Monia; Romano, Alessandra; Cavo, Michele; Arcaini, Luca; Trentin, Livio; Cattaneo, Chiara; Derenzini, Enrico; Fracchiolla, Nicola Stefano; Marchesi, Francesco; Scattolin, Annamaria; Billio, Atto; Bocchia, Monica; Massaia, Massimo; Gambacorti-Passerini, Carlo; Mauro, Francesca Romana; Gentile, Massimo; Mohamed, Sara; Della Porta, Matteo Giovanni; Coviello, Elisa; Cilloni, Daniela; Visani, Giuseppe; Federici, Augusto Bramante; Tisi, Maria Chiara; Cudillo, Laura; Galimberti, Sara; Gherlinzoni, Filippo; Pagano, Livio; Guidetti, Anna; Bertù, Lorenza; Corradini, Paolo; Passamonti, Francesco; Visco, Carlo, SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort «Hematological Oncology» , 2022 , pp. 1-11

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo